Spontaneous bacterial peritonitis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
* After a primary episode of | * After a primary episode of spontaneous bacterial peritonitis, the recurrence rate at one year is approximately 70%, with a 1-year overall survival rate of 30 to 50% in patients who do not receive [[antibiotic]] [[prophylaxis]]. | ||
* Secondary antibiotic prophylaxis in a cirrhotic patient with a prior history of SBP reduces the risk of SBP recurrence from 68% to 20%. | * Secondary antibiotic prophylaxis in a cirrhotic patient with a prior history of SBP reduces the risk of SBP recurrence from 68% to 20%. | ||
* Accordingly, most experts recommend daily long-term antimicrobial prophylaxis for patients with a history of one or more episodes of SBP. | * Accordingly, most experts recommend daily long-term antimicrobial prophylaxis for patients with a history of one or more episodes of SBP. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* Several studies have shown that oral norfloxacin 400 mg daily prevents spontaneous bacterial peritonitis in patients with low-protein ascites and those with previous history of spontaneous bacterial peritonitis (SBP). | * Several studies have shown that oral [[norfloxacin]] 400 mg daily prevents spontaneous bacterial peritonitis in patients with low-protein [[ascites]] and those with previous history of [[spontaneous bacterial peritonitis]] (SBP). | ||
* In one study, norfloxacin reduced SBP recurrence rates from 68% to 20%. | * In one study, [[norfloxacin]] reduced SBP recurrence rates from 68% to 20%. | ||
* Alternative regimens that have been studied include oral double-strength trimethoprim-sulfamethoxazole 5 doses per week or oral ciprofloxacin 750 mg once a week, but intermittent dosing may lead to resistance. | * Alternative regimens that have been studied include [[oral]] double-strength [[Sulfamethoxazole-Trimethoprim|trimethoprim-sulfamethoxazole]] 5 doses per week or oral [[ciprofloxacin]] 750 mg once a week, but intermittent dosing may lead to resistance. | ||
* In addition, prolonged use of antibiotic prophylaxis has led to the development of gram-negative bacterial resistance (to fluoroquinolones and trimethoprim-sulfamethoxazole), as well as an increased likelihood of developing gram-positive infections. | * In addition, prolonged use of antibiotic prophylaxis has led to the development of [[gram-negative]] bacterial [[resistance]] (to [[fluoroquinolones]] and [[Sulfamethoxazole-Trimethoprim|trimethoprim-sulfamethoxazole]]), as well as an increased likelihood of developing [[gram-positive]] infections. | ||
* Therefore, prophylaxis should be reserved for patients at high risk of developing SBP and daily dosing regimens are preferred. | * Therefore, prophylaxis should be reserved for patients at high risk of developing SBP and daily dosing regimens are preferred. | ||
* Daily long-term dosing with norfloxacin has been proved to be superior to in-hospital administration of norfloxacin. | * Daily long-term dosing with [[norfloxacin]] has been proved to be superior to in-hospital administration of [[norfloxacin]]. | ||
* All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref><ref name="GinésRimola1990">{{cite journal|last1=Ginés|first1=Pere|last2=Rimola|first2=Antoni|last3=Planas|first3=Ramón|last4=Vargas|first4=Victor|last5=Marco|first5=Francesc|last6=Almela|first6=Manuel|last7=Forne|first7=Montserrat|last8=Miranda|first8=Maria Luisa|last9=Llach|first9=Josep|last10=Salmerón|first10=Joan Manuel|last11=Esteve|first11=Maria|last12=Marques|first12=Josep Maria|last13=de Anta|first13=Maria Teresa Jiménez|last14=Arroyo|first14=Vicente|last15=Rodés|first15=Joan|title=Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial|journal=Hepatology|volume=12|issue=4|year=1990|pages=716–724|issn=02709139|doi=10.1002/hep.1840120416}}</ref> | * All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref><ref name="GinésRimola1990">{{cite journal|last1=Ginés|first1=Pere|last2=Rimola|first2=Antoni|last3=Planas|first3=Ramón|last4=Vargas|first4=Victor|last5=Marco|first5=Francesc|last6=Almela|first6=Manuel|last7=Forne|first7=Montserrat|last8=Miranda|first8=Maria Luisa|last9=Llach|first9=Josep|last10=Salmerón|first10=Joan Manuel|last11=Esteve|first11=Maria|last12=Marques|first12=Josep Maria|last13=de Anta|first13=Maria Teresa Jiménez|last14=Arroyo|first14=Vicente|last15=Rodés|first15=Joan|title=Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial|journal=Hepatology|volume=12|issue=4|year=1990|pages=716–724|issn=02709139|doi=10.1002/hep.1840120416}}</ref> | ||
Revision as of 18:26, 25 January 2017
|
Spontaneous bacterial peritonitis Microchapters |
|
Differentiating Spontaneous bacterial peritonitis from other Diseases |
|
Diagnosis |
|
Treatment |
|
Spontaneous bacterial peritonitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Spontaneous bacterial peritonitis secondary prevention |
|
FDA on Spontaneous bacterial peritonitis secondary prevention |
|
CDC on Spontaneous bacterial peritonitis secondary prevention |
|
Spontaneous bacterial peritonitis secondary prevention in the news |
|
Blogs on Spontaneous bacterial peritonitis secondary prevention |
|
Directions to Hospitals Treating Spontaneous bacterial peritonitis |
|
Risk calculators and risk factors for Spontaneous bacterial peritonitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Shivani Chaparala M.B.B.S [3]
Overview
- After a primary episode of spontaneous bacterial peritonitis, the recurrence rate at one year is approximately 70%, with a 1-year overall survival rate of 30 to 50% in patients who do not receive antibiotic prophylaxis.
- Secondary antibiotic prophylaxis in a cirrhotic patient with a prior history of SBP reduces the risk of SBP recurrence from 68% to 20%.
- Accordingly, most experts recommend daily long-term antimicrobial prophylaxis for patients with a history of one or more episodes of SBP.
Secondary Prevention
- Several studies have shown that oral norfloxacin 400 mg daily prevents spontaneous bacterial peritonitis in patients with low-protein ascites and those with previous history of spontaneous bacterial peritonitis (SBP).
- In one study, norfloxacin reduced SBP recurrence rates from 68% to 20%.
- Alternative regimens that have been studied include oral double-strength trimethoprim-sulfamethoxazole 5 doses per week or oral ciprofloxacin 750 mg once a week, but intermittent dosing may lead to resistance.
- In addition, prolonged use of antibiotic prophylaxis has led to the development of gram-negative bacterial resistance (to fluoroquinolones and trimethoprim-sulfamethoxazole), as well as an increased likelihood of developing gram-positive infections.
- Therefore, prophylaxis should be reserved for patients at high risk of developing SBP and daily dosing regimens are preferred.
- Daily long-term dosing with norfloxacin has been proved to be superior to in-hospital administration of norfloxacin.
- All patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). [1][2]
- Rifaximin was more effective than norfloxacin in the secondary prevention of SBP as encephalopathy-related mortality and side effects were fewer with rifaximin than norfloxacin.[5][6]
References
- ↑ http://guideline.gov/content.aspx?id=14887&search=ascitis
- ↑ Ginés, Pere; Rimola, Antoni; Planas, Ramón; Vargas, Victor; Marco, Francesc; Almela, Manuel; Forne, Montserrat; Miranda, Maria Luisa; Llach, Josep; Salmerón, Joan Manuel; Esteve, Maria; Marques, Josep Maria; de Anta, Maria Teresa Jiménez; Arroyo, Vicente; Rodés, Joan (1990). "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial". Hepatology. 12 (4): 716–724. doi:10.1002/hep.1840120416. ISSN 0270-9139.
- ↑ Runyon BA (1986). "Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis". Gastroenterology. 91 (6): 1343–6. PMID 3770358.
- ↑ Grangé JD, Roulot D, Pelletier G; et al. (1998). "Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial". J. Hepatol. 29 (3): 430–6. PMID 9764990.
- ↑ Elfert, Asem; Abo Ali, Lobna; Soliman, Samah; Ibrahim, Shimaa; Abd-Elsalam, Sherief (2016). "Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis". European Journal of Gastroenterology & Hepatology. 28 (12): 1450–1454. doi:10.1097/MEG.0000000000000724. ISSN 0954-691X.
- ↑ Dong, Tien; Aronsohn, Andrew; Gautham Reddy, K.; Te, Helen S. (2016). "Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis". Digestive Diseases and Sciences. 61 (12): 3621–3626. doi:10.1007/s10620-016-4313-0. ISSN 0163-2116.